Information Provided By:
Fly News Breaks for March 26, 2018
HOLX
Mar 26, 2018 | 08:48 EDT
Goldman Sachs analyst Isaac Ro removed Hologic from the firm's Conviction Buy list and lowered his price target on the shares to $43, stating that he sees a lack of near-term catalysts. No material news was presented at the American Academy of Dermatology meeting in late February and he expects no significant news at the American Society for Laser Medicine and Surgery meeting in April, Ro tells investors.
News For HOLX From the Last 2 Days
There are no results for your query HOLX